Skip to main content
italianoIT
European Commission logo print header

Mucosal protease and their inhibitors in inflammatory bowel disease: From etiopathogenetic insight to innovative therapy

Obiettivo

IBDase addresses the etiology and pathogenesis of inflammatory bowel disease (IBD) with a multidisciplinary plan for innovative diagnosis and therapy focused on mucosal proteases and their inhibitors (P/PIs). The incidence of IBD, a multifactorial disease influenced by environmental factors in a background of complex genetic susceptibility, is rising, particularly among European children. Current therapies lack efficacy and specificity. The gut microflora plays a crucial role in IBD but the cause for this is still poorly understood. Research implicating P/PIs in gut mucosal inflammation requires further mechanistic insight and the P/PIs relevant in human IBD need to be identified. To this end we will identify human mucosal P/PI polymorphisms affecting expression levels and/or activity of P/PIs and analyse their genotype/phenotype associations in IBD patient cohorts across Europe. IBD-associated P/PIs will be characterised by biochemical properties, expression in human clinical samples and manipulation of experimental models. Their interaction with microflora will be examined in animal models with controlled colonisation of the gut and in vitro co-culture models of intestinal mucosa and bacteria. In vivo studies will use targeted, well-established and new mouse models and evaluate zebrafish as an IBD model. Molecular mechanisms for involvement of IBD specific P/PI gene variants in the inflammatory response will be proposed. Therapeutics development will focus on specific inhibition or promotion of proteolysis in the intestinal mucosa, and select at least three validated P/PI of the intestinal mucosa for follow-up in clinical trials. Embracing the concept of tailoring treatment to individual patient characteristics to increase efficacy and reduce side-effects, IBDase strengthens international visibility of IBD related research, policies and industry and fosters IBD related research to the benefit of European society in both patient care and economic interest.

Campo scientifico

Parole chiave

Programma(i)

Argomento(i)

Invito a presentare proposte

FP7-HEALTH-2007-A
Vedi altri progetti per questo bando

Meccanismo di finanziamento

CP-FP - Small or medium-scale focused research project

Coordinatore

UNIVERSITAET BERN
Contributo UE
€ 526 950,00
Indirizzo
HOCHSCHULSTRASSE 6
3012 Bern
Svizzera

Mostra sulla mappa
Regione
Schweiz/Suisse/Svizzera Espace Mittelland Bern / Berne
Tipo di attività
Higher or Secondary Education Establishments
Contatto amministrativo
Daniel Lottaz (Dr.)
Collegamenti
Costo totale
Nessun dato

Partecipanti (9)

Condividi questa pagina

Scarica

Ultimo aggiornamento: 16 Luglio 2019

Il mio booklet

Permalink: https://cordis.europa.eu/project/id/200931/it

European Union, 2024